NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits have been initiated on behalf of Centessa Pharmaceuticals Plc shareholders CNTA and PayPal Holdings, Inc. PYPL. Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Centessa Pharmaceuticals Plc CNTA

Collection Period: May 28, 2021 – June 1, 2022 or pursuant to the Company’s IPO on May 28, 2021

Lead Plaintiff Deadline: November 28, 2022

Centessa is a clinical-stage pharmaceutical company that purports to discover, develop and deliver medicines to patients. The Company’s development pipeline includes Lixivaptan, a small molecule vasopressin V2 receptor inhibitor in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”); and ZF874, a small molecule pharmacological chaperone-fold corrector of the Z variant of the DNA-encoding protein alpha-1-antitrypsin (“A1AT”) in Phase 1 clinical development for the treatment of A1AT deficiency (“AATD”).

On April 21, 2021, Centessa filed a registration statement on Form S-1 with the US Securities and Exchange Commission (“SEC”) in connection with the IPO, which, following multiple amendments, was declared effective by the SEC on May 27. 2021 (the “Registration Statement”).

On or about May 28, 2021, Centessa completed the IPO and issued 16.5 million of its ADSs to the public at an offering price of $20 per ADS, generating proceeds for the Company of $306.9 million after deduction of costs and applicable actuarial rebates.

On June 1, 2021, Centessa filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which includes and forms a part of the registration statement (the “Prospectus” and together with the registration statement, the “Offering Documents”). .

The complaint alleges…